David Sepulveda, PA
Surgical · Gonzales, LANPI 1316100381
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Among surgical clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 392 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$696
- Takeda Pharmaceuticals U.S.A., Inc.$459
- Boehringer Ingelheim$437
- Lilly USA, LLC$354
- Novo Nordisk$317
- plus $2K from 39 others
What the payments were for
- Food & beverage$5,892100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,892 in reported general payments places this provider in the 95th percentile of 130 surgical providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $82,265 |
| JardianceEmpagliflozin | 76 | $80,257 |
| TrulicityDulaglutide | 21 | $41,639 |
| MounjaroTirzepatide | 26 | $39,812 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $29,230 |
| JanuviaSitagliptin Phosphate | 23 | $21,698 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $21,228 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $17,181 |
| FarxigaDapagliflozin Propanediol | 13 | $15,157 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 15 | $12,176 |
| KerendiaFinerenone | 11 | $12,009 |
| EliquisApixaban | 11 | $7,268 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $3,634 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 122 | $3,210 |
| Atorvastatin Calcium | 265 | $2,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr, Trijardy Xr | $437 | $130,842124 claims |
| Novo NordiskOzempic | $317 | $82,26555 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $354 | $81,45147 claims |
| GSKTrelegy Ellipta | $696 | $29,23034 claims |
| MerckJanuvia | $104 | $21,69823 claims |
| AstraZenecaFarxiga | $14 | $15,15713 claims |
| BayerKerendia | $299 | $12,00911 claims |
| PfizerEliquis | $242 | $7,26811 claims |
| AbbVieSynthroid | $1,370 | $1,53013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 surgical providers in Louisiana.
Other surgical in Gonzales
- Holly EdmondsGonzales$3K
- Courtney MoseleyShreveport$33K
- Jennifer PikerLafayette$11K
- Richard TubbsNew Orleans$9K
- Brandie HenryBaton Rouge$6K
- Jonathan FletcherBaton Rouge$5K
- Keri MorrisNew Orleans$5K
- Jamie WallaceAlexandria$5K
- Adam-Paul LanglinaisLafayette$5K
- Daniel ClaytonHouma$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.